MedTrace Logo

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

NCT07132515 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-20

No results posted yet for this study

Summary

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Conditions

  • Cirrhosis
  • HCC - Hepatocellular Carcinoma
  • Portal Vein Thrombosis

Interventions

DRUG

Enoxaparin, warfarrin, or apixaban

Enoxaparin, warfarrin, or apixaban

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2025-08-31
Completion
2025-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07132515 on ClinicalTrials.gov